Found 102 articles
Manitari Pharma received approval to begin construction of Security Level 3 safe plus grow rooms, Manitari Pharma is one step closer to obtaining Controlled Substances Dealer's Licence for Psilocybin Research
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2022.
The global urinary tract infection testing market size is expected to hit around USD 765.9 million by 2030 from valued at USD 554.1 million in 2021, growing at a CAGR of 3.66% during the forecast period 2022 to 2030.
The Roche Accelerator is designed to help companies bridge the gap between idea and proof-of-concept. It is one of several incubators recently founded by Western companies.
METiS announced officially joining the Roche Accelerator with the goal to tap into Roche’s global scientific expertise, laboratory facilities and foster collaboration discussions on formulation development and optimization with Roche Innovation Center Shanghai.
Quarterly net revenues of $137.5 million with 80% gross margin Entering a transformational period with multiple clinical catalysts expected in near-term Novocure reported financial results for the quarter ended March 31, 2022.
Novocure (NASDAQ: NVCR) today reported financial results for the fourth quarter and full year ended December 31, 2021.
METiS Therapeutics today announced the appointment of Hongming Chen, Sc.D., as President and Head of Research & Development.
Novaremed’s Non-opioid Lead Compound, NRD.E1, to be Tested in NIH HEAL Initiative Phase 2 Trial for the Treatment of Chronic Pain
Novaremed AG, a privately held clinical-stage biopharmaceutical company, announces a study with the National Institutes of Health (NIH) under which the NIH will sponsor and conduct a clinical Phase 2b study with Novaremed’s lead non-opioid development compound NRD.E1 in the treatment of painful diabetic peripheral neuropathy (PDPN).
The Cambridge, Massachusetts-based company has developed an artificial intelligence platform designed to optimize pharmaceutical formulation processes.
METiS Therapeutics Launches With $86 Million Series A Financing to Transform Drug Discovery and Delivery With Machine Learning and Artificial Intelligence
METiS Therapeutics debuts with $86 million Series A financing to harness artificial intelligence and machine learning to redefine drug discovery and delivery and develop optimal therapies for patients with serious diseases.
Novocure reported financial results for the quarter ended September 30, 2021, highlighting commercial strength and strategic investment across clinical, product development and commercial initiatives intended to fuel future growth.
Gain Therapeutics, Inc. Announces Appointment of Five Members to its Newly Formed Scientific Advisory Board (SAB)Dr. Luca Benatti to Chair SAB
Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced the formation of its Scientific Advisory Board (SAB)
RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
RepliCel Life Sciences Inc., a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that Kunihiko Suzuki has agreed to accept an appointment as a Senior Strategic Advisor to its Board of Directors with a particular focus on building the Company's enterprise in Japan.
Novaremed Expands its Pipeline of Non-opioid Treatment Candidates for Chronic Pain Indications Through Acquisition of Metys Pharmaceuticals
Novaremed AG, a privately held clinical-stage biopharmaceutical company, announces the acquisition of Metys Pharmaceuticals AG, including all of its development programs, in an all-share transaction.
Fluid Biotech Inc., a medical device start-up company in Calgary, Alberta, Canada, announced the completion of its Seed fundraising round totaling $4.7 million USD and the addition of two new members to its board of directors.
Novocure reported financial results for the quarter ended June 30, 2021, highlighting commercial strength and strategic investment across clinical, product development and commercial initiatives intended to fuel future growth.
Synchron Secures $40M in Series B led by Khosla Ventures to Launch U.S. Clinical Trials of Minimally Invasive Brain Computer Interface
Synchron, a brain interface platform company , today announced that the company has secured $40M in a eries B round of financing led by Silicon Valley venture capital firm Khosla Ventures.
Quarterly net revenues of $134.7 million with 80% gross margin Interim analysis for phase 3 pivotal LUNAR trial in non-small cell lung cancer concluded with favorable recommendation to continue the trial with reduced sample size
Statement from the Council of Chief Medical Officers of Health Implementing COVID-19 Vaccination in Canada
We recently marked the one-year anniversary of the global COVID-19 pandemic. Over the past year, people in Canada and across the world have mobilized to combat this virus and have collectively sacrificed a great deal.